The effect research of specific immunotherapy of allergic rhinitis and allergic rhinitis combined bronchial asthma.
- Author:
Bangyu DENG
;
Yunxia ZHAO
;
Yiwen YOU
- Publication Type:Journal Article
- MeSH:
Allergens;
immunology;
Animals;
Asthma;
therapy;
Dermatophagoides farinae;
immunology;
Dermatophagoides pteronyssinus;
immunology;
Humans;
Immunoglobulin E;
blood;
Immunotherapy;
Interleukin-4;
blood;
Rhinitis, Allergic;
therapy;
Treatment Outcome
- From:
Journal of Clinical Otorhinolaryngology Head and Neck Surgery
2015;29(12):1090-1093
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To study the therapeutic effects of the specific immunotherapy (SIT) on allergic rhinitis and allergic rhinitis combined bronchial asthma. METHED: All patients were classified into allergic rhinitis group (AR group) with 32 patients and allergic rhinitis combined bronchial asthma group (AR+BA group) with 32 patients. Another health control group with 32 cases was designed as well. The allergens,symptom scores and therapeutic effects of the former two-group patients were analysis, and the serums of all three-group cases were extracted to evaluate the specific Immunoglobin E(sIgE), Interleukin-4 (IL-4). The SPSS13. 0 package was applied to conduct t-test and chi-square test, and the difference of P<0. 05 was regarded as statistical significance.
RESULT:The main allergens of 64 patients were dermatophagoides farinae and dermatophagoides pteronyssinus. The improvement of symptom scores before and after SIT was statistical significant with P<0. 05. Although total effective rate reached 100% , AR group was superior than AR+BA group in term of the efficacy comparison, and P<0. 05 indicated the statistical significance. The serum sIgE, IL-4 values of three groups were brought into comparison, and P<0. 05 indicated the statistical significance of the difference.
CONCLUSION:The SIT on the AR, AR+BA is a safe and effective treatment, but different disease responds diversely. The long-term treatment course is recommended.
